HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Kim H, Ng D, Matheson M, et al.

Puberty Is Associated with Decline in Estimated Glomerular Filtration Rate in Children with CKD

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:43A 2020

BACKGROUND

Puberty is a high-risk period for decline in kidney function among children with CKD. We aimed to describe changes in eGFR before and after pubertal onset using different objective markers of puberty among children with CKD.

METHODS

We conducted a prospective cohort study using data from the Chronic Kidney Disease in Children (CKiD) study. Children who had onset of CKD after pubertal onset were excluded. GFR was estimated annually using the bedside and complete CKiD equations. Pubertal onset was defined by three separate definitions: transition to Tanner Stage 2, peak growth velocity, and menarche. A mixed effects model with random intercept and random slope was used to compare the slope of eGFR before and after pubertal onset. The model was adjusted for age, race, glomerular diagnosis, baseline proteinuria, and BMI.

RESULTS

339 girls and 552 boys were included; Median age of pubertal onset for girls was 11.0 years (IQR 9.8, 12.1), 14.1 years (IQR 12.4, 17.0), and 14.4 years (IQR 13.1, 15.7) as defined by Tanner stage 2, peak growth velocity, and menarche, respectively. Median age of pubertal onset for boys was 12.4 years (11.3, 13.3) and 14.6 years (IQR 13.4, 16.6) as defined by Tanner stage 2 and peak growth velocity, respectively. Annual percent change in eGFR declined faster among girls and boys after pubertal onset when defined by all measures, after adjustment. For example, annual percent decrease in eGFR was seen to increase from 2.6% prior to 9.0% after Tanner stage 2 in boys using the complete CKiD equation (p<0.001).

CONCLUSION

Estimated GFR declined faster after the onset of puberty among girls and boys with CKD. Clinicians should be aware that puberty may be an important time of kidney function decline among children with CKD.

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.